|
Mexico looking for India to procure essential drugs
|
|
Laxmi Yadav, Mumbai
June 15 , 2022
|
|
|
The Mexican government is looking for Indian drug exporters having Good Manufacturing Practice (GMP) certificates from stringent regulatory authorities in the United States, European Union, United Kingdom, Switzerland, Canada and Australia to procure essential drugs.
The drugs include paracetamol, hydrocortisone & methylprednisolone injectable solution, phenytoin, heparin injectable solution, alibour powder, aluminum and magnesium chewable tablet, conjugated estrogens, atosiban injectable solution, nitrofural ovule, hydralazine injectable solution, dextromethorphan syrup, prednisolone-sulfacetamide, oxcarbazepine, glucose, sodium chloride, polygelin, glyceryl trinitrate, dinoprostone. Gel, erythropoietin, amino acids, lapatinib, mifepristone, ibuprofen, levomepromazine, tramadol, somatropin, morphine etc.
The Mexican Institute of Health and Wellness (INSABI) last week launched a new tender process for procuring above medicines which will help the Mexican government widen the range of suppliers in the public health sector.
Pharmaceuticals Export Promotion Council of India (Pharmexcil) has received a communication from the Embassy of Mexico in India seeking assistance in the procurement of select pharma products via a newly launched tender process.
“The Mexican government is urgently looking for Indian exporters capable of manufacturing the listed products, and have GMP certificates from stringent regulatory authorities in the US, EU, UK, Switzerland, Canada or Australia. This would allow the registration procedure at COFEPRIS (Mexican regulatory authority) to be started at the time of shipping and speed up the registration process,” said Uday Bhaskar, director general, Pharmexcil.
Since the tendering process is in Spanish and needs to be completed in Compranet online portal (https://compranet.hacienda.gob.mx/), exporters are advised to have a representative based in Mexico, said Bhaskar.
The closing date for applying for the tender is June 17, 2022.
However, companies which are interested in filing the tender but lack local representatives in Mexico can contact Min. Judith Arrieta at the Embassy of Mexico for further guidance, he added.
Given the time bound nature of this request and the deadline for filing the tender, member companies are requested to file the tender at the earliest, he stated.
The Latin American country relies heavily on pharmaceutical imports to meet domestic demand for certain medicines. It is the second-largest drugs market in Latin America, after Brazil.
Mexico is one of Latin America's most developed markets, with regulatory standards superior to most of its southern neighbors. It has strong trade links to the US, Canada and the EU. It has a competitive and well-developed pharmaceutical manufacturing industry, including around 200 companies and substantial presence of multinationals.
Despite increased production by the local pharmaceutical industry due to Covid-19, most of the reported increase is on the medical device and consumables segments. Over the long term, Mexico may be an attractive market for multinational pharmaceutical firms, due to the country's large patient base, relatively well-developed regulatory landscape, and rising demand for chronic disease treatment. Forecasts say decelerating growth in pharmaceutical spending over the next decade as the government looks to contain healthcare spending growth, said a report released by Pharmexcil.
Mostly driven by an ageing population and the increasing incidence of chronic diseases, forecasts say that over the next 5 years, Mexican pharmaceutical sales will grow at a compound annual growth rate (CAGR) of 2.2 per cent and reach US$ 10.9 billion. Mexico's generic drug market will experience strong growth in the long term, driven by a rapidly increasing population and improvements to healthcare insurance coverage. The value of the Mexican generic drug market will increase from US$ 3.2 billion in 2019 to US$ 6 billion in 2029, reflecting a compound annual growth rate (CAGR) of 6.2 per cent, the report added.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|